What if your cancer is so hard to treat... because no one’s targeting the real causes?

In this deep-dive episode, Dr. Dino Prato, founder of Envita Medical Centers, explains the true nature of treatment resistance in cancer — and why standard care often falls short. From mutations and mitochondrial dysfunction to hidden infections and immune evasion, most patients are only getting a fraction of the story.

🎯 What You’ll Learn:

• Why cancer is biphasic: mitochondrial and mutational drivers
  
  
• How toxins, infections (like EBV, Lyme, fungi), and hypoxia feed cancer
  
  
• Why standard chemo may actually cause resistance and immune collapse
  
  
• How DAMPs, NK cells, and targeted chemo can flip the immune system back on
  
  
• The role of precision testing: RNA, spatial biology, tumor microenvironment
  
  
• How interventional radiology (TACE) delivers chemo directly to tumors with less damage
  
  

📊 In our clinical experience, patients receiving precision-based, low-dose, and interventional therapies have shown reduced side effects, improved outcomes, and better quality of life.

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493